Partners Regeneron and Bayer are hoping to piggy-back on their success with the wet age-related macular degeneration blockbuster Eylea, reuniting to develop a new drug that could become part of a combination therapy for the disease.
For years, Cell Therapeutics CEO Jim Bianco has boasted about the company's long-standing relationship with Novartis. But as of this morning, the relationship is history.
Cambridge, MA's Moderna Therapeutics is marching on with another high-dollar deal, getting $125 million up front to lend its messenger RNA platform to rare disease luminary Alexion Pharmaceuticals.
Sanofi is doubling down on its RNAi development deal with Alnylam. The pharma giant says it will pay a hefty premium to buy up a 12% stake in the biotech, investing $700 million and greatly expanding its rights to Alnylam's lead drug along with a portfolio of current and prospective therapies.
Dutch InteRNA Technologies is collaborating with the Neuroallianz Consortium, an academic industry partnership with Belgium-based UCB and the Rheinische Friedrich-Wilhelms-University of Bonn in Germany, to develop and study microRNA therapeutics in neurodegenerative diseases.
Contract researcher Avillion launched last year with a novel approach to contract drug development, planning to team up with Big Pharmas on late-stage assets and take drugs to the finish line in exchange for a cut of the proceeds. Now the London company has reeled in a big-name partner in Pfizer, signing on to run a Phase III study of the cancer-fighting Bosulif.
Over the last 6 months or so, Johnson & Johnson's ($JNJ) big new innovation initiative has been bringing together deal teams in key R&D hot spots around the world with an eye to laying claim to some of the most important new technologies surfacing in the industry.
When it comes to Alzheimer's research, success stories are few and far between. Therapeutic programs center around vaccines and drugs, but Akili Interactive Labs wants to change all that: The Boston-based startup recently signed a deal with Pfizer to see if its mobile video game platform can help diagnose early signs of Alzheimer's.
Three years ago, Roche sent shockwaves ricocheting through the R&D field when it decided to write off a half-billion dollar initiative in RNA drug research and sell off its dedicated facility in Wisconsin. But a year after John Reed took over at Roche's Basel-based research group pRED, Roche is once again doing RNA deals.
Dako has sealed a deal with yet another Big Pharma company to develop companion diagnostic tests for potential new cancer drugs. This time, it will work with Merck, a pharmaceutical giant facing some turmoil as it revamps its struggling R&D operations.